|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.82 USD | +0.47% |
|
+3.47% | -6.49% |
| Jan. 15 | Myriad Genetics, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 03:45 PM | |
| Jan. 15 | Myriad Genetics Expects Higher Q4 Revenue, Provides 2025 Guidance | MT |
Myriad Genetics, Inc. revised earnings guidance for the year 2024. For the year, the company expects revised revenue to be in the range of $837 million to $843 million compared to previously expected guidance to be in the range of $835 million to $845 million.
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 6,101.24PTS | -0.29% | +1.74% | - | ||
| 12.82USD | +0.47% | +3.47% | 1.17B | ||
